Newsroom
PRX302 (topsalysin) clinical trial opens at Imperial College NHS Trust
A clinical trial evaluating a promising new treatment for localised clinically significant prostate cancer
A clinical trial evaluating a promising new treatment for localised clinically significant prostate cancer has opened at Imperial College Healthcare NHS Trust. Professor is the global Chief Investigator of this study running in sites across the UK and the USA looking to demonstrate whether PRX302 (topsalysin) can effectively treat prostate cancer with minimal side-effects.
Related articles
-
Prostagram to screen for prostate cancer a step closer
British scientists develop a new scan for prostate cancer
-
Focal therapy using HIFU and cryotherapy have similar cancer control to prostatectomy
New hope of better lifestyle outcomes for prostate cancer patients
-
New hope of better lifestyle outcomes for prostate cancer patients
A new study has given real hope of better post-treatment lifestyle outcomes for men suffering with prostate cancer.